Toggle Health Problems and D

Rheumatic diseases not helped by Vitamin D – if you ignore what and how much was given – meta-analysis June 2017

Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis

Medicine: June 2017 - Volume 96 - Issue 23 - p e7024; doi: 10.1097/MD.0000000000007024
Franco, André Silva MDa; Freitas, Thiago Quadrantea; Bernardo, Wanderley M. MD, PhDb; Pereira, Rosa Maria R. MD, PhDa,*

 Download the PDF from VitaminDWiki

Background: Vitamin D serum levels and the presence and activity of rheumatic conditions have been associated. However, many studies are merely observational, and the existent randomized clinical trials were never systematically analyzed. Therefore, this study aims to provide a systematic review and meta-analysis of such a topic.

Methods: MEDLINE, EMBASE, LILACS, COCHRANE, and CINAHL were explored to identify randomized trials that investigated clinical repercussions of vitamin D (or analogs) supplementation for at least 3 months in rheumatic diseases. Standardized clinical and/or laboratorial outcomes related to disease activity were analyzed according to each disease before and after supplementation.

Results: Database searches rendered 668 results; 9 were included—5 on rheumatoid arthritis, 3 on systemic lupus erythematosus, and 1 on systemic sclerosis. Seven of the studies were meta-analyzed. After vitamin D supplementation, rheumatoid arthritis recurrence decreased; however, not significantly (risk difference = −0.10, 95% CI = −0.21, 0.00, P = .05). No statistical significance was observed regarding visual analog scale (mean difference = 2.79, 95% CI = −1.87, 7.44, P = .24) and disease activity score28 (mean difference = −0.31, 95% CI = −0.86, 0.25, P = .28). Regarding systemic lupus erythematosus, anti-dsDNA positivity was significantly reduced (risk difference = −0.10, 95% CI = −0.18, −0.03; P = .005).

Conclusion: Vitamin D supplementation reduced anti-dsDNA positivity on systemic lupus erythematosus and could possibly reduce rheumatoid arthritis recurrence, although novel randomized clinical trials are needed to confirm and extend the benefits of this hormone in immune-mediated rheumatic diseases.

Created by admin. Last Modification: Tuesday June 13, 2017 14:25:29 GMT-0000 by admin. (Version 4)

Attached files

ID Name Comment Uploaded Size Downloads
8102 RA Meta June 2017.pdf admin 13 Jun, 2017 452.75 Kb 815